In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat

White House proposal to use march-in rights to lower drug prices alarms pharma, with profits and intellectual property rights at stake.

January 22, 2024 Check out STAT+

Sponsored By

Kayana Szymczak for STAT STAT+ | In 'march-in' rights, some see a tool to lower drug prices. Others see a threat to intellectual property White House proposal to use march-in rights to lower drug prices alarms pharma, with profits and intellectual property rights at stake. By Ed Silverman New tool for tracing blood cells' ancestry might one day help predict disease risk A way to track changes in human blood cells in real-time might one day be used to predict disease risk years before symptoms show up. By Megan Molteni STAT+ | A Harvard course seeks to put food on the table in medical education Medical schools have been criticized for inadequate training on nutrition. A new course seeks to remedy that with emerging physicians. By Elizabeth Cooney Molly Ferguson for STAT Why many more people are lining up for a flu shot than a Covid vaccine A combination of factors likely leads to the disparities, according to people who study vaccine acceptance and vaccine hesitancy. By Helen Branswell STAT+ | Physician buy-in will make or break VC firm General Catalyst's bold hospital deal Doctors and other clinicians have their own way of doing things. Will a VC firm like General Catalyst be able to come in and turn that around? By Tara Bannow STAT+ | Gilead's Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike. By Matthew Herper Adobe Opinion: The FDA and FTC need to crack down on TikTok and Instagram influencers pitching prescription drugs Influencers with no medical training regularly use TikTok and Instagram to promote prescription drugs. It's time for more rules. By Sneha Dave and Sydney Reed and Steven Woloshin

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser